Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2024;35(1):150-5
Article Links
New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature
Michail Krikelis1, Evgenia Papathanasiou2, George Leonidakis2, Pavlos Pardalis2, Spyridon Michopoulos2, Evanthia Zampeli2
Authors Information

1Greek Rheumatology Society and Professional Association of Rheumatologists, Private Practice, Greece

2Gastroenterology Department, Alexandra General Hospital, Athens, Greece

 

M Krikelis, E Papathanasiou, G Leonidakis, P Pardalis, S Michopoulos, E Zampeli

Keywords: IL-17 inhibitor, inflammatory bowel disease
References
  1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015 Sep 5;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7.
  2. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis 2020 Mar 13;14(3):351-60. doi: 10.1093/ecco-jcc/jjz152.
  3. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 2018 Feb;29(1):13-8. doi: 10.1080/09546634.2017.1329511.
  4. Orzan OA, Țieranu CG, Olteanu AO, Dorobanțu AM, Cojocaru A, Mihai MM, et al. An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics 2023 Aug 21;15(8):2171. doi: 10.3390/pharmaceutics15082171.
  5. Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021 Mar 30;12:622934. doi: 10.3389/fimmu.2021.622934.
  6. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004 Jan;110(1):55-62. doi: 10.1016/j.clim.2003.09.013.
  7. Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS One 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781.
  8. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668.
  9. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity 2015 Oct 20;43(4):727-38. doi: 10.1016/j.immuni.2015.09.003.
  10. Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol 2023 Mar 23;14:1124628. doi: 10.3389/fphar.2023.1124628.
  11. Truong SL, Chin J, Liew DFL, Zahir SF, Ryan EG, Rubel D, et al. Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. Rheumatol Ther 2021 Dec;8(4):1603-1616. doi: 10.1007/s40744-021-00360-6.
  12. Orrell KA, Murphrey M, Kelm RC, Lee HH, Pease DR, Laumann AE, et al. Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program. J Am Acad Dermatol 2018 Oct;79(4):777-778. doi: 10.1016/j.jaad.2018.06.024.
  13. Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019 May 14;25(18):2162-2176. doi: 10.3748/wjg.v25.i18.2162.
  14. Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020 Aug;16(8):415-433. doi: 10.1038/s41584-020-0454-9.
  15. Zioga N, Kogias D, Lampropoulou V, Kafalis N, Papagoras C. Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology. Mediterr J Rheumatol 2022 Apr 15;33(Suppl 1):126-36. doi: 10.31138/mjr.33.1.126.
  16. Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020 Sep;79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927.
  17. Machado PM, Deodhar A. Treat-to-target in axial spondyloarthritis: gold standard or fools' gold? Curr Opin Rheumatol 2019 Jul;31(4):344-8. doi: 10.1097/BOR.0000000000000625.